scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024
scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection
scPharmaceuticals Inc. (NASDAQ: SCPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update